Donald S. Baim

TL;DR: Six recently completed coronary stent trials and associated nonrandomized registries that enrolled 6186 patients treated with ≥1 coronary stents followed by antiplatelet therapy with aspirin and ticlopidine were pooled for this analysis and the variables most significantly associated with the probability of stent thrombosis were persistent dissection NHLBI grade B or higher after stenting.

TL;DR: In a low-risk clinical trial population, the clinical outcome beyond 1 year after stenting is determined by a high rate of events related to disease progression in segments other than the stented lesion, which itself remains relatively stable.

TL;DR: A study in patients with stents provides a potent model for evaluating the role of smooth muscle cell hyperplasia in restenosis independent of any contribution from elastic recoil or vasospasm, and the effect of disease states such as diabetes on specific components of restenotic.

TL;DR: Conservative strategy seems to be the preferred initial management strategy for percutaneous transluminal coronary angioplasty after thrombolytic therapy for acute myocardial infarction, with equally good short- and long-term outcome with less morbidity and a lower use of PTCA.

TL;DR: The long-term outcome after this procedure can be predicted on the basis of patients' base-line characteristics, and patients with two or three risk factors had a predicted five-year event-free survival rate of only 13 to 41 percent.